Log in

NASDAQ:INSM - Insmed Stock Price, Forecast & News

$23.21
+0.07 (+0.30 %)
(As of 12/16/2019 06:00 AM ET)
Today's Range
$22.94
Now: $23.21
$23.36
50-Day Range
$17.26
MA: $20.73
$23.36
52-Week Range
$11.31
Now: $23.21
$33.13
Volume569,477 shs
Average Volume806,433 shs
Market Capitalization$2.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.04
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.84 million
Book Value$2.70 per share

Profitability

Net Income$-324,280,000.00
Net Margins-291.19%

Miscellaneous

Employees373
Market Cap$2.07 billion
Next Earnings Date2/28/2020 (Estimated)
OptionableOptionable

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.


Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) announced its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.01. The biopharmaceutical company earned $38.89 million during the quarter, compared to analysts' expectations of $35.89 million. Insmed had a negative net margin of 291.19% and a negative return on equity of 114.68%. During the same quarter in the prior year, the company earned ($1.14) EPS. View Insmed's Earnings History.

When is Insmed's next earnings date?

Insmed is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Insmed.

What price target have analysts set for INSM?

6 analysts have issued 1-year price objectives for Insmed's shares. Their forecasts range from $30.00 to $52.00. On average, they anticipate Insmed's stock price to reach $40.50 in the next year. This suggests a possible upside of 74.5% from the stock's current price. View Analyst Price Targets for Insmed.

What is the consensus analysts' recommendation for Insmed?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.

What are Wall Street analysts saying about Insmed stock?

Here are some recent quotes from research analysts about Insmed stock:
  • 1. According to Zacks Investment Research, "Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. " (9/27/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $52/share is based on: (a) $51/share, as a 35x multiple of taxed and diluted FY28 GAAP EPS of $7.58 discounted back to and (b) an NPV of $52/share, (discount rate 12.0%, growth rate 2%), with both methods arriving at this target. Risks to our investment thesis and target price include: (1) failure of ALIS in the (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates and/or pricing or other limiting factors." (4/9/2019)

Has Insmed been receiving favorable news coverage?

Press coverage about INSM stock has trended negative on Monday, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insmed earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Insmed.

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Capstone Turbine (CPST), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), CHIMERA INVT CO/SH NEW (CIM), Celgene (CELG), Geron (GERN), Gilead Sciences (GILD), Johnson & Johnson (JNJ), B2Gold (BTG) and InMed Pharmaceuticals (IMLFF).

Who are Insmed's key executives?

Insmed's management team includes the folowing people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

Who are Insmed's major shareholders?

Insmed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (1.71%), Emerald Advisers LLC (1.10%), Emerald Mutual Fund Advisers Trust (1.02%), Point72 Asset Management L.P. (0.80%), Voya Investment Management LLC (0.71%) and Orbimed Advisors LLC (0.63%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.

Which institutional investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Point72 Asset Management L.P., Stifel Financial Corp and Rice Hall James & Associates LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Donald J Hayden Jr, John Goll, Orlov S Nicole Schaeffer and William Lewis. View Insider Buying and Selling for Insmed.

Which institutional investors are buying Insmed stock?

INSM stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Granahan Investment Management Inc. MA, Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, Voya Investment Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC and C WorldWide Group Holding A S. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $23.21.

How big of a company is Insmed?

Insmed has a market capitalization of $2.07 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Insmed employs 373 workers across the globe.View Additional Information About Insmed.

What is Insmed's official website?

The official website for Insmed is http://www.insmed.com/.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]


MarketBeat Community Rating for Insmed (NASDAQ INSM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  425 (Vote Underperform)
Total Votes:  840
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel